MP74-04 EXPRESSION OF ANDROGEN AND ESTROGEN SIGNALING COMPONENTS AND STEM CELL MARKERS PREDICT CANCER PROGRESSION AND CANCER-SPECIFIC SURVIVAL IN PATIENTS WITH METASTATIC PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Markers I1 Apr 2014MP74-04 EXPRESSION OF ANDROGEN AND ESTROGEN SIGNALING COMPONENTS AND STEM CELL MARKERS PREDICT CANCER PROGRESSION AND CANCER-SPECIFIC SURVIVAL IN PATIENTS WITH METASTATIC PROSTATE CANCER Tetsuya Fujimura, Satoru Takahashi, Tomohiko Urano, Kenichi Takayama, Toru Sugihara, Daisuke Obinata, Yuta Yamada, Jimpei Kumagai, Haruki Kume, Satoshi Inoue, and Yukio Homma Tetsuya FujimuraTetsuya Fujimura More articles by this author , Satoru TakahashiSatoru Takahashi More articles by this author , Tomohiko UranoTomohiko Urano More articles by this author , Kenichi TakayamaKenichi Takayama More articles by this author , Toru SugiharaToru Sugihara More articles by this author , Daisuke ObinataDaisuke Obinata More articles by this author , Yuta YamadaYuta Yamada More articles by this author , Jimpei KumagaiJimpei Kumagai More articles by this author , Haruki KumeHaruki Kume More articles by this author , Satoshi InoueSatoshi Inoue More articles by this author , and Yukio HommaYukio Homma More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.2337AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Genes of androgen and estrogen signaling and stem cell (SC)-like cells have crucial roles in prostate cancer (PC). This study aimed to predict clinical failure (CF) by estimating these PC-related genes. METHODS We developed models to predict CF using biopsy samples from a training set of 46 and independent validation set of 30 patients with bony metastatic PC. Cancerous and stromal tissues were separately collected by laser-captured microdissection. The association between mRNA expression of the following genes and CF was analyzed: androgen receptor (AR) and its related genes (APP, FOX family, TRIM 36, Oct1, and ACSL 3), stem cell (SC)-like molecules (Klf4, c-Myc, Oct 3/4, and Sox2), estrogen receptor (ER), Her2, PSA, and CRP. RESULTS Logistic analyses to predict PSA recurrence showed an area under the curve (AUC) of 1.0 in both sets for Sox2, Her2, and CRP expression in cancer cells; AR and ERα expression in stromal cells; and clinical parameters. We identified 10 prognostic factors for cancer-specific survival (CSS): Oct1, TRIM36, Sox2, and c-Myc expression in cancer cells; AR, Klf4, and ERƒ¿ expression in stromal cells; and PSA, Gleason score, and extent of disease. On the basis of these factors, patients were divided into favorable-, intermediate-, and poor-risk groups according to the number of factors present. Five-year CSS rates for the 3 groups were 90%, 32%, and 12% in training set and 75%, 48%, and 0% in validation set, respectively (Figure 1). CONCLUSIONS Expression levels of androgen and estrogen signaling components and SC markers are powerful prognostic tools. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e857 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Tetsuya Fujimura More articles by this author Satoru Takahashi More articles by this author Tomohiko Urano More articles by this author Kenichi Takayama More articles by this author Toru Sugihara More articles by this author Daisuke Obinata More articles by this author Yuta Yamada More articles by this author Jimpei Kumagai More articles by this author Haruki Kume More articles by this author Satoshi Inoue More articles by this author Yukio Homma More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...